Introduction: A New Approach to Knee Pain Relief

Knee osteoarthritis is a common cause of ongoing pain and stiffness for many adults, often impacting everyday life and movement. As the cushioning cartilage wears down, joints become painful and stiff, leaving many people searching for effective solutions. Surgery can seem daunting, so many look for less invasive treatments. Among these, Arthrosamid injections have recently become popular in the UK as a fresh way to ease knee pain, especially for those with mild to moderate symptoms.

This article will explain what Arthrosamid injections are, how they work, and why they’re considered a promising addition to modern osteoarthritis treatment. We’ll keep the language clear and patient-friendly, helping you understand if this therapy might be right for you.

What Is Arthrosamid and How Does It Work?

Arthrosamid is a special type of injectable hydrogel made from polyacrylamide. This gel is safe to use inside the body and works by absorbing water, mimicking the natural cushioning that healthy cartilage provides. Unlike steroids or hyaluronic acid injections that mainly reduce inflammation temporarily, Arthrosamid offers long-term physical support in the joint.

The treatment involves injecting the gel directly into the knee joint, where it gently spreads and integrates with the surrounding tissues. This restores cushioning between the bones and improves lubrication on the joint surfaces, reducing friction and pain, while helping you move more easily.

It’s normal to experience some mild discomfort or swelling right after the injection, but this usually passes quickly. You can often expect to notice improvements in pain and mobility within about four weeks. Supporting this, research has found “statistically significant data… at both 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post injection.” In fact, benefits have been shown to last even longer: “further continuation… provided statistically significant results at 2 years” (Cole et al., 2022).

Importantly, the hydrogel used in Arthrosamid has been tested for safety in laboratory studies on human nerve cells, showing “no statistically significant effects on cell survival, non-apoptotic and apoptotic cell death, or the neurite network area” (Walmod et al., 2025). This helps reassure patients about the treatment’s safety.

Advantages Over Traditional Treatments

Arthrosamid stands out from common treatments like corticosteroids, hyaluronic acid, or surgery. Steroids can provide quick but short-term relief, while surgery is invasive and requires longer recovery. Arthrosamid, on the other hand, is minimally invasive and offers lasting cushioning inside the joint.

When comparing “arthrosamid vs surgery,” the injection involves fewer risks, can be done as a day procedure, and avoids lengthy downtime. Patients often experience fewer side effects than with some traditional treatments.

Clinical studies confirm its safety: “Injection of PAAG hydrogel into the knee has been shown to be safe with no long-lasting adverse events reported” (Cole et al., 2022). Other recent research compared Arthrosamid (iPAAG) to hyaluronic acid and steroids, concluding it “offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited. It may be a complementary option in individualised osteoarthritis management” (Aykaç et al., 2025).

Interestingly, patients treated with Arthrosamid showed the “highest patient acceptable symptom state rates (72%, 54%, and 42% at 3, 6, and 12 months) and greatest minimal clinically important difference achievement at 3 and 6 months” compared to other injections (Aykaç et al., 2025).

This treatment is most suitable for those with mild to moderate osteoarthritis who haven’t found enough relief with less invasive methods. It’s important to consult a specialist to see if Arthrosamid is right for your specific condition.

Expert Care: The Key to Good Results

Professionals like Professor Paul Lee, an expert in cartilage health and orthopaedics, lead the way in offering treatments such as Arthrosamid. With extensive experience in surgery and rehabilitation, and leadership roles including with the Royal College of Surgeons of Edinburgh, Professor Lee exemplifies the expert care behind such advanced therapies.

Clinics such as MSK Doctors provide patient-focused care with a multidisciplinary team approach. While these experts don’t claim to have invented Arthrosamid, they ensure you access some of the latest and most effective treatments for musculoskeletal health.

Looking Ahead: What Should Patients Keep in Mind?

To sum up, Arthrosamid represents a significant step forward as a minimally invasive, long-lasting option for managing knee osteoarthritis pain. As noted by Cole et al. (2022), “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years.” By restoring cushioning and lubrication in the joint, it offers an innovative way to ease discomfort and improve movement—often without surgery.

If you’re considering options, it’s important to speak with a knowledgeable specialist who can assess your condition and recommend the best course of action. Staying informed and open to new research on hydrogel treatments helps you take an active role in managing your arthritis.

This article aims to be a reliable starting point for those looking to begin a well-informed conversation about their arthritis care.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(18), e44655. https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430